CALL FOR PAPERS
SPECIAL ISSUE: DRUG CRYPTOMARKETS
INTERNATIONAL JOURNAL OF DRUG POLICY
Guest editors:
Monica Barratt and Judith Aldridge
Cryptomarkets (or ‘dark net markets’) are digital platforms that use anonymising software (e.g. Tor) and cryptocurrencies (e.g. Bitcoin) to facilitate trade of goods and services. Their emergence has facilitated transnational access to a wide range of high-quality psychoactive substances. Cryptomarkets are similar to open markets (e.g. so-called street markets) in the sense that trades can occur between strangers; however, cryptomarkets also offer the advantage of relatively efficient inbuilt trust mechanisms such as rating systems and forum discussions.
We invite papers that critically examine and advance our knowledge of drug cryptomarkets. The extent and quality of the submitted abstracts will determine whether we publish a full issue or a themed cluster of papers.
Abstracts (not exceeding 350 words) are invited that address the following questions:
- What are the scope and scale of cryptomarkets?
- How are cryptomarkets located within other internet structures (dark web, deep web, etc.)?
- How are the drug use and harm/benefit trajectories of cryptomarket users affected by these new supply modes, compared with conventional drug market configurations?
- How do cryptomarkets respond to threats from scams and law enforcement efforts?
- What challenges do cryptomarkets pose for drug policy?
- How is sense of community understood and enacted within the cryptomarket environment?
- What is the potential for harm reduction digital outreach in cryptomarket environments?
- To what extent do cryptomarkets flatten hierarchical supply network chains? What are the implications of their effects on network structures for drug markets?
- To what extent can new drug trends emerging from cryptomarkets complement existing drug trend monitoring systems?
- What are the methodological and ethical issues that arise from researching cryptomarkets?
- How can participatory research models be implemented successfully in this space?
- Any other research questions not mentioned above that relate to the theme.
We anticipate a wide range of disciplinary approaches will be included in this volume, as the topic invites consideration from sociological, criminological, economic, historical, epidemiological and policy perspectives. Qualitative, quantitative, and mixed-methods research are welcome. Papers must discuss the implications of their findings for drug policy.
We invite six types of contributions (NB: in rare circumstances word limits may be exceeded with permission from the editors):
- Research papers: Research papers are usually based on original empirical analyses, but may also be discursive critical essays. These papers are usually between 3,000 and 5,000 words.
- Research methods papers: These papers explore methodological innovations in the field and are usually between 3,000 and 5,000 words.
- Commentary: These papers explore in depth a particular topic or issue for debate, and may also include evidence and analysis. The Editor may invite expert responses to commentaries for publication in the same issue. Commentaries are usually between 2,500 and 4,000 words.
- Viewpoint: Short comments and opinion pieces of up to 1,200 words which raise an issue for discussion, or comprise a case report on an issue relevant to research, policy, or practice.
- Policy or historical analysis: These are focused specifically around contemporary or historical analyses of policies and their impacts, and are usually between 3,000 and 5,000 words.
- Review: These papers seek to review systematically a particular area of research, intervention, or policy. Reviews are usually between 4,000 and 8,000 words.
Abstracts should be emailed to m.barratt@unsw.edu.au and to judith.aldridge@manchester.ac.uk by Friday 10 April 2015. The email subject heading should read “IJDP Special Issue”. The editors will inform authors by Friday 1 May whether to proceed to full submission. If selected, complete manuscripts will be due Friday 7 August. All manuscripts are subject to the normal IJDP peer review process. Accepted papers will be available online from late 2015 and the special issue or section will be published in print in early 2016.
For more information about the International Journal of Drug Policy, see: http://www.journals.elsevier.com/international-journal-of-drug-policy/